Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Co-Diagnostics Inc (CODX)

Co-Diagnostics Inc (CODX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,535
  • Shares Outstanding, K 60,893
  • Annual Sales, $ 3,920 K
  • Annual Income, $ -37,640 K
  • EBIT $ -34 M
  • EBITDA $ -33 M
  • 60-Month Beta 1.15
  • Price/Sales 5.55
  • Price/Cash Flow N/A
  • Price/Book 0.55
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.99
  • Most Recent Earnings $-0.16 on 11/13/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Services

Options Overview Details

View History
  • Implied Volatility 321.84% (+15.60%)
  • Historical Volatility 448.57%
  • IV Percentile 54%
  • IV Rank 27.88%
  • IV High 921.55% on 10/22/25
  • IV Low 90.00% on 03/25/25
  • Expected Move (DTE 7) 0.1615 (43.12%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 1,930
  • Volume Avg (30-Day) 1,451
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 14,019
  • Open Int (30-Day) 19,231
  • Expected Range 0.2130 to 0.5360

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.13
  • Number of Estimates 1
  • High Estimate -0.13
  • Low Estimate -0.13
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +63.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3111 +20.38%
on 11/18/25
0.4286 -12.62%
on 11/10/25
-0.0176 (-4.49%)
since 11/05/25
3-Month
0.2989 +25.29%
on 09/10/25
1.5500 -75.84%
on 10/27/25
+0.0647 (+20.88%)
since 09/05/25
52-Week
0.2275 +64.62%
on 05/23/25
1.5500 -75.84%
on 10/27/25
-0.4455 (-54.33%)
since 12/05/24

Most Recent Stories

More News
Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health

SALT LAKE CITY , Nov. 20, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development...

CODX : 0.3745 (-3.10%)
Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dxâ„¢ PCR Platform to Support Submission to the U.S. FDA

SALT LAKE CITY , Nov. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development...

CODX : 0.3745 (-3.10%)
Co-Diagnostics Reports Third Quarter 2025 Financial Results

SALT LAKE CITY , Nov. 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics," "Co-Dx," or "the Company") , a molecular diagnostics company with a unique, patented platform...

CODX : 0.3745 (-3.10%)
Utah Governor Cox and BioUtah Recognize Co-Diagnostics Following Recent JV Announcement in Kingdom of Saudi Arabia

SALT LAKE CITY , Nov. 12, 2025 /PRNewswire/ -- Governor Spencer Cox joins Kelvyn Cullimore of BioUtah in recognizing Co-Diagnostics, Inc. (Nasdaq: CODX) , a Utah diagnostics company with a patented...

CODX : 0.3745 (-3.10%)
Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics Pvt. Ltd

SALT LAKE CITY , Nov. 5, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a patented platform for developing advanced...

CODX : 0.3745 (-3.10%)
Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dxâ„¢ Primer Aiâ„¢ Platform

Company forms new AI business unit, led by Chief Technology & AI Officer Christopher Thurston, to unify and advance Co-Dx's existing and future AI initiatives

CODX : 0.3745 (-3.10%)
Co-Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast

SALT LAKE CITY , Oct. 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic...

CODX : 0.3745 (-3.10%)
Co-Diagnostics to Host Fireside Chat on November 5th with CEO, Dwight Egan, to Discuss Recently Announced Definitive Agreement in Saudi Arabia

SALT LAKE CITY , Oct. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development...

CODX : 0.3745 (-3.10%)
Co-Diagnostics, Inc. Announces Closing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

SALT LAKE CITY , Oct. 29, 2025 /PRNewswire/ -- Co-Diagnostics, Inc.  (Nasdaq: CODX)  (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development...

CODX : 0.3745 (-3.10%)
Co-Diagnostics, Inc. Announces Pricing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

SALT LAKE CITY , Oct. 28, 2025 /PRNewswire/ -- Co-Diagnostics, Inc.  (Nasdaq: CODX)  (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development...

CODX : 0.3745 (-3.10%)

Business Summary

Co-Diagnostics Inc. is a molecular diagnostics company. It develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests which are designed using the detection and/or analysis of nucleic acid molecules. It also uses proprietary technology...

See More

Key Turning Points

3rd Resistance Point 0.4230
2nd Resistance Point 0.4115
1st Resistance Point 0.3930
Last Price 0.3745
1st Support Level 0.3630
2nd Support Level 0.3515
3rd Support Level 0.3330

See More

52-Week High 1.5500
Fibonacci 61.8% 1.0448
Fibonacci 50% 0.8887
Fibonacci 38.2% 0.7327
Last Price 0.3745
52-Week Low 0.2275

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar